Markets:

Overview

News

Currencies

International

Treasuries

Bristol-Myers Squibb (NY:BMY)

61.99 +2.47 (+4.15%)

Official Closing Price Updated: 7:00 PM EST, Feb 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9

...

86 87 Next >

The Great Pipeline Grab: Life Sciences Deal Volume Skyrockets 82% as Big Pharma Battles the Patent Cliff

February 06, 2026

The life sciences sector has entered 2026 in the midst of a historic transformation, as deal volume and value surged by a staggering 82% over the past year. This "Great Rebound," fueled by a...

Via MarketMinute

Roivant Sciences (ROIV): Anatomy of a 15% Surge and the Future of the ‘Vant’ Model

February 06, 2026

As of February 6, 2026, Roivant Sciences (Nasdaq: ROIV) has firmly established itself as the preeminent "capital allocator" of the biotechnology sector. The company made headlines today with a...

Via Finterra

Topics ETFs Economy Initial Public Offering

Bristol Myers Squibb Co (NYSE:BMY) Beats Q4 2025 Earnings Estimates and Provides Strong 2026 Outlook ↗

February 05, 2026

Via Chartmill

Bristol-Myers Squibb Co (NYSE:BMY) Shows Strong Technical Setup for Potential Breakout ↗

January 28, 2026

Via Chartmill

Bristol-Myers Squibb Co (NYSE:BMY): A High-Yield Dividend Stock With a Path to Growth ↗

January 17, 2026

Via Chartmill

BMY Q4 Deep Dive: Growth Portfolio Offsets Legacy Pressure, Pipeline Readouts in Focus

February 06, 2026

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) beat Wall Street’s revenue expectations in Q4 CY2025, with sales up 1.4% year on year to $12.5 billion. The company’s full-year revenue...

Via StockStory

Why Bristol Myers Squibb Stock Topped the Market Today ↗

February 05, 2026

At the end of last year, the company did particularly well with its lineup of newer medications.

Via The Motley Fool

Bristol Myers (BMY) Q4 2025 Earnings Transcript ↗

February 05, 2026

Bristol Myers (BMY) Q4 2025 Earnings Transcript

Via The Motley Fool

Bristol-Myers Squibb (NYSE:BMY) Reports Strong Q4 CY2025

February 05, 2026

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced better-than-expected revenue in Q4 CY2025, with sales up 1.4% year on year to $12.5 billion. The company’s full-year revenue guidance...

Via StockStory

Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2025

February 05, 2026

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Teams Up with Kasey Keller to Share His Lymphoma Journey with Breyanzi

February 04, 2026

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Q4 Earnings Preview: Profits Under Pressure Even As Wall Street Bets On 2026 Pipeline ↗

February 04, 2026

The drugmaker is relying on its newer pipeline to offset Eliquis' upcoming patent cliff in 2028.

Via Stocktwits

Topics Artificial Intelligence Intellectual Property Workforce

Bristol-Myers Squibb Earnings: What To Look For From BMY

February 03, 2026

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be announcing earnings results this Thursday before the bell. Here’s what to expect.

Via StockStory

Bristol Myers Squibb Introduces "Change the Target. Change What’s Possible.” to Highlight Unmet Needs in Cardiovascular and Thromboembolic Care

February 03, 2026

From Bristol Myers Squibb

Via Business Wire

The Pharma Reckoning: 2026 Earnings Unveil a New Era of 'TrumpRx' Deals and Looming Patent Cliffs

February 02, 2026

As the pharmaceutical industry enters the heart of its Q4 2025 earnings season this February 2, 2026, a clear divide has emerged between the high-flying giants of the metabolic gold rush and those...

Via MarketMinute

Topics Economy Government Intellectual Property

The Sound of Silence: Revolution Medicines Plummets 17% as M&A Hopes Evaporate

February 02, 2026

The high-stakes world of biotechnology faced a jarring reality check on January 26, 2026, as shares of Revolution Medicines (Nasdaq: RVMD) cratered by 17%. The sharp decline came as the speculative...

Via MarketMinute

Topics ETFs Government Initial Public Offering

3 Top Dividend Stocks Yielding More Than 4% to Buy Hand Over Fist This Year ↗

January 30, 2026

All three can provide you with solid, consistent income.

Via The Motley Fool

Topics Artificial Intelligence Intellectual Property World Trade

3 Unpopular Stocks That Concern Us

January 28, 2026

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other...

Via StockStory

The Post-Keytruda Pivot: Inside Merck’s Strategic Evolution and the RVMD Landscape

January 26, 2026

As of January 26, 2026, Merck & Co. (NYSE: MRK) stands at the most critical juncture in its 135-year history. Known globally for its dominant oncology franchise and robust vaccine portfolio, the...

Via Finterra

Topics Artificial Intelligence Economy Intellectual Property

The $6 Billion Disconnect: Why Revolution Medicines (RVMD) Plunged 20% After Merck Talks Collapsed

January 26, 2026

The biotechnology sector has always been a high-stakes arena where clinical success can create multi-billion-dollar empires overnight, and a failed negotiation can erase a fifth of a company’s market...

Via Finterra

Topics Economy Initial Public Offering

2 Under-the-Radar Biotech Stocks Set to Boom in 2026 ↗

January 24, 2026

Biotech headwinds are driving double-digit revenue growth and profitability for these two mid-caps.

Via The Motley Fool

Topics ETFs Intellectual Property World Trade

AI Bubble or Sustainable Growth? Here Are 2 Healthcare Companies Harnessing AI for the Long Term. ↗

January 23, 2026

Artificial intelligence may be all the rage in the technology sector, but it's also having a huge impact on healthcare.

Via The Motley Fool

Topics Artificial Intelligence

Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead? ↗

January 23, 2026

Eli Lilly's valuation has been driven higher by investor excitement around GLP-1 drugs, leaving other drugmakers languishing.

Via The Motley Fool

Resilience in the Face of the Patent Cliff: Johnson & Johnson Forecasts Landmark 2026 Growth

January 22, 2026

NEW BRUNSWICK, N.J. – Johnson & Johnson (NYSE: JNJ) has signaled a definitive turning point in its corporate evolution, issuing a robust 2026 financial outlook that defies the gravity of the...

Via MarketMinute

Topics Earnings Economy Intellectual Property

The Best Stocks to Invest $1,000 in Right Now ↗

January 21, 2026

Large, well-run dividend-paying companies with attractive yields are out there if you look hard enough.

Via The Motley Fool

Topics Intellectual Property

Bristol Myers Squibb Announces Collaboration with Microsoft to Advance AI-Driven Early Detection of Lung Cancer

January 20, 2026

From Bristol Myers Squibb

Via Business Wire

2 Dividend Stocks to Buy and Hold For 10 Years ↗

January 19, 2026

They are unlikely to resort to dividend cuts anytime soon.

Via The Motley Fool

Topics Intellectual Property

2 Buffett Stocks to Load Up On—And 1 to Ditch ↗

January 19, 2026

Via MarketBeat

The Execution Engine: How Merck is Dominating the 2026 Pharma Landscape

January 15, 2026

As of January 15, 2026, Merck & Co. (NYSE: MRK) has emerged as the standout performer in the pharmaceutical sector, defying the gravity of looming patent expirations with a series of strategic...

Via MarketMinute

Topics Economy Intellectual Property

Thursday's session: gap up and gap down stock in the S&P500 index ↗

January 15, 2026

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9

...

86 87 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.